Clinical trial NCT03546452: A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC
Official title: A Prospective Study to Evaluate the Results of Different NGS- Panels in Mutation Detection and Tumor Mutation Burden(TMB) Calculation by Using Malignant Hydrothorax From NSCLC
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Malignant Hydrothorax
NSCLC
Keywords: NSCLC
malignant hydrothorax
prospective study
Lead sponsor: Shanghai Chest Hospital
Sponsor class: OTHER
Collaborators: name: Sinotech Genomics Co., Ltd
name: Amoy Diagnostics
name: Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
name: Geneplus-Beijing Co. Ltd.
name: Berry Genomics Co., Ltd.
First posted: 2018-06-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients in shanghai chest hospital

Brief summary: A prospective study to evaluate consistency of different NGS-panel. Cell free DNA is purified from each malignant hydrothorax from NSCLC .Different NGS-panels are applied to perform in vitro diagnosis to detect Single Nucleotide Variants(SNV) and to calculate TMB value in these DNA samples.Consistency of enrolled NGS-panels are then evaluated by statistical analysis.

Detailed description: 1. Chest Hospital in accordance with the clinical requirements of the treatment required to extract ML hydrothorax sent to hospital pathology department for exfoliated Cell diagnosis and production of cell wax block, while the additional responsibility for the extraction of hydrothorax 500ml, and collect 10ml venous blood sample, Venous blood samples are stored in either the A cell-free DNA Blood collection Tube (STRECK tube) or the ethylenediaminetetraacetic acid(EDTA) anticoagulant tube.
2. Amoy Diagnostics Co., Ltd. (AmoyDx) is responsible for plasma separation after sampling 2 hours, plasma is frozen by the chest Hospital, AmoyDx completes the purification of peripheral blood cells genomic DNA , and which is divided into 6 parts ,5 of which are send to in vitro diagnostic products (IVD) enterprises to perform NGS-Panel detection.
3. 100ml hydrothorax is send to each IVD enterprise.
4. Each IVD enterprise carries on the hydrothorax cell free DNA and peripheral blood cell genomic DNA NGS-Panel detection according to their own protocol.
5. Each IVD enterprise will complete the test within 7-10 working days and fill out the results in accordance with the report template provided by this research project (provided by Guangzhou Burning Rock Medical Examination Institute Co., Ltd.) and submit to sponsor by email.
6. Sponsor would use whole exon panel (WES) to obtain an TMB value if needed.
7. Employ four-grid analysis to evaluate positive compliance rate, negative compliance rate, total compliance rate of all submitted data.
8. Employ kappa test to evaluate the consistency of each two detections.

Eligibility criteria: Inclusion Criteria:

* Advanced malignant lung cancer, with treatment of pleural effusion, hydrothorax volume not less than 800ml

Exclusion Criteria:

* The sample size is not sufficient to detect.
* There are not enough tumor cells in the tissue section to be evaluated through the pathology department of the chest Hospital.

Primary outcomes:
measure: Evaluate consistency of TMB value of different NGS-Panel
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shangha Chest Hospital
state: Shanghai
Study officials:
affiliation: Shanghai Chest Hospital
name: shun lu, Prof.
role: PRINCIPAL_INVESTIGATOR
References: